Contact
searchSearch
HMP Global
Login

Schizophrenia News

strand of DNA
News
Genetic Liability for Schizophrenia May Affect Traumatic Brain Injury Associations
04/21/2025
Jolynn Tumolo
A genetic liability for schizophrenia and other mental disorders appears to factor into the associations between traumatic brain injury and mental disorder and suicide, according to study findings.
A genetic liability for schizophrenia and other mental disorders appears to factor into the associations between traumatic brain injury and mental disorder and suicide, according to study findings.
A genetic liability for...
04/21/2025
Psych Congress Network
injection for schizophrenia treatment
News
Antipsychotic Sedation Peaks in First 2 Weeks, Emphasizing Importance of Early Monitoring
04/21/2025
Maria Mantas
A meta-analysis of randomized controlled trials (RCTs) of antipsychotic monotherapy for the acute phase of schizophrenia and schizoaffective disorder (SSD) found that sedation onset peaked within the first 2 weeks of treatment initiation.
A meta-analysis of randomized controlled trials (RCTs) of antipsychotic monotherapy for the acute phase of schizophrenia and schizoaffective disorder (SSD) found that sedation onset peaked within the first 2 weeks of treatment initiation.
A meta-analysis of randomized...
04/21/2025
Psych Congress Network
stethoscope with research images in background medical study clinical trial research
News
Machine Learning Predicts Progression to Schizophrenia Within 5 Years
03/12/2025
Jolynn Tumolo
Machine learning models used routine clinical data from electronic health records to predict progression to schizophrenia and bipolar disorder within 5 years for patients with pre-existing mental illness, according to a study published in...
Machine learning models used routine clinical data from electronic health records to predict progression to schizophrenia and bipolar disorder within 5 years for patients with pre-existing mental illness, according to a study published in...
Machine learning models used...
03/12/2025
Psych Congress Network
two researchers look at computer screen in lab medical research
News
Continuous D2 Blockade in First-Episode Schizophrenia Does Not Raise Relapse Risk
03/05/2025
Jolynn Tumolo
More than 5 years of continuous treatment with dopamine D2 receptor-blocking long-acting injectable (LAI) antipsychotics does not appear to increase the risk of breakthrough psychosis in patients with first-episode schizophrenia.
More than 5 years of continuous treatment with dopamine D2 receptor-blocking long-acting injectable (LAI) antipsychotics does not appear to increase the risk of breakthrough psychosis in patients with first-episode schizophrenia.
More than 5 years of continuous...
03/05/2025
Psych Congress Network
two illustrated heads in profile, one orange and one blue, with slight overlap between the two in the middle of the picture
News
Researchers Advise Screening for Manic Symptoms in Patients With Schizophrenia
02/25/2025
Jolynn Tumolo
Screening revealed distinct symptoms of mania in more than a quarter of stable outpatients with schizophrenia spectrum disorders (SSD), according to a study published in Brain Medicine.
Screening revealed distinct symptoms of mania in more than a quarter of stable outpatients with schizophrenia spectrum disorders (SSD), according to a study published in Brain Medicine.
Screening revealed distinct...
02/25/2025
Psych Congress Network
A person sits holding a pill in one hand and a glass of water in the other
News
Iclepertin Shows No Benefit for Cognitive Function in Schizophrenia
01/23/2025
Brionna Mendoza
A Phase II clinical trial evaluating the efficacy of iclepertin (BI 425809), a glycine transporter-1 inhibitor, in treating cognitive impairment associated with schizophrenia (CIAS) showed no significant differences in cognitive outcomes...
A Phase II clinical trial evaluating the efficacy of iclepertin (BI 425809), a glycine transporter-1 inhibitor, in treating cognitive impairment associated with schizophrenia (CIAS) showed no significant differences in cognitive outcomes...
A Phase II clinical trial...
01/23/2025
Psych Congress Network
brain waves schizophrenia transcranial magnetic stimulation
News
Review Questions Utility of tDCS for Cognitive Symptoms in Schizophrenia
01/08/2025
Brionna Mendoza
A recent meta-analysis questions the effectiveness of transcranial direct current stimulation (tDCS) for improving cognitive impairments in individuals with schizophrenia after finding no statistically significant difference in cognitive...
A recent meta-analysis questions the effectiveness of transcranial direct current stimulation (tDCS) for improving cognitive impairments in individuals with schizophrenia after finding no statistically significant difference in cognitive...
A recent meta-analysis questions...
01/08/2025
Psych Congress Network
An illustrated picture shows two cartoon doctors, one holding up a magnifying glass to a cartoon brain.
News
Analysis Estimates 0.45% Schizophrenia Prevalence in United States
12/10/2024
Jolynn Tumolo
More patients with schizophrenia are covered by Medicare and Medicaid compared with commercial payers in the United States, according to results from a 2022 claims analysis presented in a poster at Psych Congress. “Among the Medicaid...
More patients with schizophrenia are covered by Medicare and Medicaid compared with commercial payers in the United States, according to results from a 2022 claims analysis presented in a poster at Psych Congress. “Among the Medicaid...
More patients with schizophrenia...
12/10/2024
Psych Congress Network
woman schizophrenia depression smart phone
News
Cognitive Symptoms May Be as Burdensome as Psychosis for Patients Living With Schizophrenia
12/04/2024
Brionna Mendoza
Patients living with schizophrenia discussed cognitive symptoms of the disease less often than psychotic symptoms, cognitive and other negative symptoms were “perceived” as “equally burdensome” as the positive symptoms of the disease due to...
Patients living with schizophrenia discussed cognitive symptoms of the disease less often than psychotic symptoms, cognitive and other negative symptoms were “perceived” as “equally burdensome” as the positive symptoms of the disease due to...
Patients living with...
12/04/2024
Psych Congress Network
a caregiver speaks with a doctor
News
Caregivers Confirm Usability of Schizophrenia Cognition Rating Scale
11/14/2024
Jolynn Tumolo
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving...
11/14/2024
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use